Logo

Who's Writing the Biggest R&D Checks?

Dec 02, 2010

Big Biotech may not spend as much on research and development as Big Pharma, but it manages to spend a pretty penny in the pursuit of new drugs and treatments, according to Fierce Biotech’s John Carroll. And when it comes to the "biggest spenders" in biotech, the US takes the cake, boasting 11 of the top 15 largest global companies in the field. The top five are all American, Carroll adds. Amgen was the top spender in 2010, with a budget of $2.72 billion. Biogen Idec takes second ($1.2 billion), Gilead third ($849 million), Genzyme is fourth ($805 million), and Celgene rounds off the top five ($745 million).

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.